These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28891260)
1. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Saba CF; Vickery KR; Clifford CA; Burgess KE; Phillips B; Vail DM; Wright ZM; Morges MA; Fan TM; Thamm DH Vet Comp Oncol; 2018 Mar; 16(1):E76-E82. PubMed ID: 28891260 [TBL] [Abstract][Full Text] [Related]
2. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378 [TBL] [Abstract][Full Text] [Related]
3. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Saba CF; Clifford C; Burgess K; Phillips B; Vail D; Wright Z; Curran K; Fan T; Elmslie R; Post G; Thamm D Vet Comp Oncol; 2020 Dec; 18(4):763-769. PubMed ID: 32346934 [TBL] [Abstract][Full Text] [Related]
4. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs. Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697 [TBL] [Abstract][Full Text] [Related]
5. Alternating rabacfosadine and doxorubicin for treatment of naïve canine lymphoma. Saba CF; Fan TM; Phillips BS; Wright ZM; Thamm DH Vet Comp Oncol; 2024 Jun; 22(2):278-283. PubMed ID: 38616055 [TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. Morges MA; Burton JH; Saba CF; Vail DM; Burgess KE; Thamm DH J Vet Intern Med; 2014; 28(5):1569-74. PubMed ID: 25274443 [TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma. Weishaar KM; Wright ZM; Rosenberg MP; Post GS; McDaniel JA; Clifford CA; Phillips BS; Bergman PJ; Randall EK; Avery AC; Thamm DH; Christman Hull AA; Gust CM; Donoghue AR J Vet Intern Med; 2022 Jan; 36(1):215-226. PubMed ID: 34952995 [TBL] [Abstract][Full Text] [Related]
8. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Reiser H; Wang J; Chong L; Watkins WJ; Ray AS; Shibata R; Birkus G; Cihlar T; Wu S; Li B; Liu X; Henne IN; Wolfgang GH; Desai M; Rhodes GR; Fridland A; Lee WA; Plunkett W; Vail D; Thamm DH; Jeraj R; Tumas DB Clin Cancer Res; 2008 May; 14(9):2824-32. PubMed ID: 18451250 [TBL] [Abstract][Full Text] [Related]
9. Tanovea® for the treatment of lymphoma in dogs. De Clercq E Biochem Pharmacol; 2018 Aug; 154():265-269. PubMed ID: 29778492 [TBL] [Abstract][Full Text] [Related]
10. GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. Thamm DH; Vail DM; Kurzman ID; Babusis D; Ray AS; Sousa-Powers N; Tumas DB BMC Vet Res; 2014 Jan; 10():30. PubMed ID: 24460928 [TBL] [Abstract][Full Text] [Related]
11. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Vail DM; Thamm DH; Reiser H; Ray AS; Wolfgang GH; Watkins WJ; Babusis D; Henne IN; Hawkins MJ; Kurzman ID; Jeraj R; Vanderhoek M; Plaza S; Anderson C; Wessel MA; Robat C; Lawrence J; Tumas DB Clin Cancer Res; 2009 May; 15(10):3503-10. PubMed ID: 19417014 [TBL] [Abstract][Full Text] [Related]
12. Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. Back AR; Schleis SE; Smrkovski OA; Lee J; Smith AN; Phillips JC Vet Comp Oncol; 2015 Dec; 13(4):398-408. PubMed ID: 23910023 [TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. Al-Nadaf S; Rebhun RB; Curran KM; Venable RO; Skorupski KA; Willcox JL; Burton JH BMC Vet Res; 2018 Nov; 14(1):356. PubMed ID: 30458771 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. Lucroy MD; Phillips BS; Kraegel SA; Simonson ER; Madewell BR J Vet Intern Med; 1998; 12(5):325-9. PubMed ID: 9773407 [TBL] [Abstract][Full Text] [Related]
15. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013). Gillem J; Giuffrida M; Krick E Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827 [TBL] [Abstract][Full Text] [Related]
17. Oral melphalan for the treatment of relapsed canine lymphoma. Mastromauro ML; Suter SE; Hauck ML; Hess PR Vet Comp Oncol; 2018 Mar; 16(1):E123-E129. PubMed ID: 28941072 [TBL] [Abstract][Full Text] [Related]
18. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs. Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354 [TBL] [Abstract][Full Text] [Related]
19. Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma. Higginbotham ML; McCaw DL; Roush JK; Nietfeld JC; Wilkerson MJ; Reeds K; Burr D J Am Anim Hosp Assoc; 2013; 49(6):357-62. PubMed ID: 24051255 [TBL] [Abstract][Full Text] [Related]
20. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]